NO3137093T3 - - Google Patents

Info

Publication number
NO3137093T3
NO3137093T3 NO15720059A NO15720059A NO3137093T3 NO 3137093 T3 NO3137093 T3 NO 3137093T3 NO 15720059 A NO15720059 A NO 15720059A NO 15720059 A NO15720059 A NO 15720059A NO 3137093 T3 NO3137093 T3 NO 3137093T3
Authority
NO
Norway
Application number
NO15720059A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3137093T3 publication Critical patent/NO3137093T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO15720059A 2014-04-29 2015-04-29 NO3137093T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14166354 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059339 WO2015165966A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
NO3137093T3 true NO3137093T3 (de) 2018-02-10

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15720059A NO3137093T3 (de) 2014-04-29 2015-04-29

Country Status (18)

Country Link
US (1) US10478454B2 (de)
EP (2) EP3137093B1 (de)
JP (1) JP6692755B2 (de)
KR (1) KR102388363B1 (de)
CN (1) CN106659738B (de)
AU (1) AU2015254663B2 (de)
CA (1) CA2946928C (de)
CY (1) CY1119674T1 (de)
DK (1) DK3137093T3 (de)
ES (2) ES2651537T3 (de)
HR (1) HRP20171896T1 (de)
HU (1) HUE037501T2 (de)
LT (1) LT3137093T (de)
NO (1) NO3137093T3 (de)
PL (1) PL3137093T3 (de)
PT (1) PT3137093T (de)
SI (1) SI3137093T1 (de)
WO (1) WO2015165966A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
CN106535924A (zh) 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3440593A (en) * 1993-01-14 1994-08-15 Nelson Arispe Methods and compositions for blocking amyloid protein ion channels
WO1999009981A1 (en) * 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20130011431A1 (en) * 2010-03-29 2013-01-10 Novartis Ag Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant

Also Published As

Publication number Publication date
CA2946928C (en) 2023-01-31
SI3137093T1 (en) 2018-01-31
EP3137093B1 (de) 2017-09-13
CN106659738B (zh) 2021-02-09
US20170049812A1 (en) 2017-02-23
AU2015254663A1 (en) 2016-11-10
EP3269376B1 (de) 2020-07-15
DK3137093T3 (en) 2017-12-11
AU2015254663B2 (en) 2020-04-02
CN106659738A (zh) 2017-05-10
LT3137093T (lt) 2017-12-11
EP3269376A1 (de) 2018-01-17
JP2017518275A (ja) 2017-07-06
WO2015165966A1 (en) 2015-11-05
KR20160145822A (ko) 2016-12-20
PL3137093T3 (pl) 2018-06-29
ES2824763T3 (es) 2021-05-13
JP6692755B2 (ja) 2020-05-13
PT3137093T (pt) 2017-12-19
HUE037501T2 (hu) 2018-08-28
HRP20171896T1 (hr) 2018-02-23
ES2651537T3 (es) 2018-01-29
KR102388363B1 (ko) 2022-04-19
US10478454B2 (en) 2019-11-19
CA2946928A1 (en) 2015-11-05
CY1119674T1 (el) 2018-04-04
EP3137093A1 (de) 2017-03-08

Similar Documents

Publication Publication Date Title
BR112016018935A2 (de)
BR112016010711A2 (de)
BR112016017283A2 (de)
BR112016018369A2 (de)
JP1543656S (de)
BR112016021334A2 (de)
BR112016021982A2 (de)
BR112016019460A2 (de)
BR112016022869A2 (de)
BR112016016534A2 (de)
BR112016017093A2 (de)
BR112016028002A2 (de)
BR112016020283A2 (de)
BR112016011451A2 (de)
BR112016030921A2 (de)
BR112016025806A2 (de)
BR112016019537A2 (de)
BR112016020166A2 (de)
BR112016015527A2 (de)
BR112016030130A2 (de)
BR112016018822A2 (de)
BR112016025637A2 (de)
NO3137093T3 (de)
BR112016000460A2 (de)
JP1520089S (de)